Company intelligence / Profile preview

Inveready

Ownership: Private
Employees: ~25
Development stage: Other

Overview

Inveready does not develop drugs itself but invests in early-stage life science and biotech firms developing therapies for human health. Their funds have supported multiple programs from preclinical through clinical phases in various indications such as oncology and pain management.

Therapeutic areas: NeurologyOncology
Modalities: Small moleculeBiologicMonoclonal antibodyGene therapy
Industry: Investors

Partnerships

EIC FundCTI Life Sciences Fund

Beyond the preview

Go deeper on Inveready.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Inveready.

Explore the full profile